News
VVOS
0.6410
-7.10%
-0.0490
Weekly Report: what happened at VVOS last week (0511-0515)?
Weekly Report · 1h ago
Vivos Therapeutics Delays Quarterly Filing
TipRanks · 2d ago
Vivos Therapeutics delays Q1 10-Q filing, seeks SEC extension
PUBT · 2d ago
Weekly Report: what happened at VVOS last week (0504-0508)?
Weekly Report · 05/11 09:00
Weekly Report: what happened at VVOS last week (0427-0501)?
Weekly Report · 05/04 09:00
Weekly Report: what happened at VVOS last week (0420-0424)?
Weekly Report · 04/27 09:00
Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges
TipRanks · 04/22 21:03
Vivos Therapeutics gets Nasdaq notice for failing minimum stockholders’ equity rule
PUBT · 04/22 20:42
Qorvo To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 04/22 12:48
Vivos Therapeutics Price Target Cut to $3.00/Share From $5.50 by Ascendiant Capital
Dow Jones · 04/22 10:09
Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 04/22 10:09
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3
Benzinga · 04/22 09:59
Weekly Report: what happened at VVOS last week (0413-0417)?
Weekly Report · 04/20 09:00
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics
Barchart · 04/18 05:00
Vivos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/17 15:04
Vivos Therapeutics Price Target Cut to $2.50/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 04/17 15:04
HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5
Benzinga · 04/17 14:55
Analysts Conflicted on These Healthcare Names: Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health (OPCH)
TipRanks · 04/17 14:00
Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright
TipRanks · 04/17 13:52
VIVOS THERAPEUTICS, INC. <VVOS.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $2.5 FROM $7
Reuters · 04/17 13:46
More
Webull provides a variety of real-time VVOS stock news. You can receive the latest news about Vivos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VVOS
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.